Search
Estazolam
go.drugbank.com/drugs/DB01215ApprovedIllicitInvestigationalIt has been shown in some cases to be more potent than diazepam or nitrazepam.
Ixazomib
go.drugbank.com/drugs/DB09570ApprovedInvestigational[L51244] It was also investigated in other hematological malignancies as well as other conditions, such as systemic light chain (AL) amyloidosis, graft-versus-host disease, and lupus nephritis. … [A264319] It was later approved by Health Canada on August 3, 2016,[L51239] and by the EMA on November 21, 2016.
Dalfampridine
go.drugbank.com/drugs/DB06637ApprovedInvestigationalThis is the first drug that was specifically approved to help with mobility in these patients. FDA approved on January 22, 2010.
Chlordiazepoxide
go.drugbank.com/drugs/DB00475ApprovedIllicitIt has also been used in the symptomatic treatment of alcohol withdrawal.
Prucalopride
go.drugbank.com/drugs/DB06480ApprovedInvestigational[A37348] The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies. … [A40254] Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009,[A40250] in Canada on December 7, 2011 and by the FDA on December 17, 2018.[L4880]
Alprostadil
go.drugbank.com/drugs/DB00770ApprovedInvestigationalAlprostadil is a chemically-identical synthetic form of prostaglandin E1 (PGE1), a potent vasodilator produced endogenously. In 1996, the FDA approved the use of alprostadil, administered either with an intracavernosal injection or an in...
Ethinamate
go.drugbank.com/drugs/DB01031ApprovedIllicitWithdrawnEthinamate is a short-acting sedative-hypnotic medication used to treat insomnia. Like many such similar medications, the regular use of ethinamate can result in the development of drug tolerance in a patient. Nevertheless, the medicatio...
Dactinomycin
go.drugbank.com/drugs/DB00970ApprovedInvestigationalAs a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)
Synonyms: 2-amino-N,N'-bis(hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1H-pyrrolo(2,1-i)(1,4,7,10,13)oxatetra-azacyclohexadecin-10-yl)-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide, N,N'-((2-AMINO-4,6-DIMETHYL-3-OXO-3H-PHENOXAZINE-1,9-DIYL)-BIS(CARBONYLIMINO(2-HYDROXYPROPYLIDENE)CARBONYLIMINOISOBUTYLIDENECARBONYL-1,2-PYRROLIDINEDIYLCARBONYL(METHYLIMINO)METHYLENECARBONYL))BIS(N-METHYL-L-VALINENefazodone
go.drugbank.com/drugs/DB01149ApprovedWithdrawnIts sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. … Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or even death, with the incidence of severe liver damage was shown to be approximately 1 in 250,000 to
Adefovir dipivoxil
go.drugbank.com/drugs/DB00718ApprovedAdefovir dipivoxil, previously called bis-POM PMEA, with trade names Preveon and Hepsera, is an orally-administered acyclic nucleotide analog reverse transcriptase inhibitor (ntRTI) used for treatment
Synonyms: bis-POM PMEA